期刊文献+

人膀胱癌体外药物敏感性预测与临床应用 被引量:2

Drug Susceptibility Trial in Vitro and Clinical Application in Human Bladder Neoplasms
下载PDF
导出
摘要 目的:探讨人膀胱癌体外药敏试验在膀胱癌术后选药预防复发中的作用。方法:药物选用MMC、ADMHPT、BCG、榄香稀乳。采用MTT法分别计算5种药物对人膀胱癌细胞的抑制率。并选择抑制率最高的药物应用于临床。结果:所选5种药物对膀胱癌均有敏感性。但榄香稀乳始终显示出对癌细胞的抑制率最高,并获得临床证实。另外,在所选药物中抑制率与药物浓度呈正相关。结论:人膀胱癌体外药物敏感性研究为膀胱癌术后灌注化疗的选药提供了一种更有针对性的方法。 Objective:To study the effect of drug susceptibility trial in vitro in human bladder neoplasms for preventing the recurrence of bladder tumor after operation.Methods:The sensitivity rate of MMC,ADM,HPT,BCG and Elemene emulsion for inhibiting human bladder cancer cells were detected by MTT method,and the most sensitive drug was used clinically.Results:All of the above mentioned medicines could effectively inhibit the bladder cancer cells,but among them elemene is the most sensitive one,and the growth inhibition rate was directly correlated with the concentration.Conclusion:The drug susceptiblity trial provides an approach to aim directly in selecting medicine for intravesical instillation in preventing the recurrence of bladder cancer after operation.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2001年第11期838-840,共3页 Chinese Journal of Clinical Oncology
关键词 膀胱癌 药物敏感性试验 体外培养 临床应用 术后化疗 Bladder neoplasm Drug susceptibility In vitro
  • 相关文献

参考文献5

二级参考文献24

  • 1张万岭,王华庆,李丽庆.抗癌新药榄香烯乳胸腔内灌注治疗恶性胸水Ⅱ期临床小结[J].中国肿瘤临床,1996,23(1):75-75. 被引量:17
  • 2陈仕平,许恩赐,林震,翁明高,黄玲,江玮,蔡伟忠,叶传忠.N-CWS膀胱灌注预防膀胱癌术后复发的远期疗效观察[J].中华泌尿外科杂志,1996,17(7):412-414. 被引量:9
  • 3李启忠,周国平,丁德刚,任凤鸣,范小玲,费继光.榄香烯乳治疗与预防膀胱肿瘤复发[J].中国肿瘤临床,1996,23(9):676-677. 被引量:6
  • 4王凤,国外医学泌尿系统分册,1993年,13卷,120页
  • 5冷江涌,中华泌尿外科杂志,1990年,11卷,345页
  • 6Lamm DL. Prophylaxis for recurrent transitional cell carcinoma. Urology,1991,37(suppl 5):21.
  • 7Nakagawa S, Kojima M, Nakao M, et al. Fluorescence,microscopic study on absorption of adriamycin through the rat bladder epithelium. Tohoku J Exp Med,1987,153: 227.
  • 8Matamura Y, Tsushima T O zaki Y , et al ,Intravesical chemotherapy with 4'-epi-adriamycin in patients with superficial bladder tumours. Cancer Chemother Pharmacol, 1986,16.
  • 9Calais da Silva F.Denis L,Bono A.et al. Intravesical chemoresection with 4`-epidoxorubicin in patients with superficial bladder tumours. Eur Urol, 1988,4 : 207.
  • 10Cumming, JA, Kirk D, Newling DW, et al. A multicentre phase I study of intravesical epirubicin in the treatment of superficial bladder turnout. Eur Urol,1990,17:20.

共引文献135

同被引文献16

  • 1何士元 Dekernion JB.表浅膀胱癌的治疗[J].中华泌尿外科杂志,1988,9(1):55-55.
  • 2何有华 何秋香.尿脱落细胞学检查在膀胱癌诊断中的应用[A]..[C].全国泌尿外科五届三次会议论文汇编,1988.55.
  • 3夏溟 容石藏美孚 等.TUR-BT术后单次膀胱灌注化疗预防表浅性膀胱癌复发的价值[A]..全国泌尿外科五届三次会议论文汇编[C].,1988.111.
  • 4王广有 魏乃军 马腾骧 等.尿细胞学检查在膀胱癌术后随访中的应用[J].临床泌尿外科杂志,1988,3(3):173-174.
  • 5Kim HE,Oh JH,Lee SK,et al.Ginsenoside Rh2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen-andcaspase-dependent but Bcl-X(L)-independent pathway[J].Life Sci,1999,65(3):PL33-40.
  • 6Tatsuka M,Maeda M,Ota T.Anticarcinogenic effect and enhancement of metastatic potential of BALB/c3T3 cells by ginsenoside Rh(2)[J].Jpn J Cancer Res,2001,92(11):1184-1189.
  • 7WargovichM J.Colon cancer chemop revention with ginseng andother botanicals[J].J Korean Med Sci,2001,16(Supp)l:81-86.
  • 8Kim YS,Jin SH,Lee YH,et al.Differential expression of protein kinase C subtypes during ginsenoside Rh2-induced apoptosis in SK-N-BE(2) and C6 Bu-l cells[J].Arch Pharm Res,2000,23(5):518-524.
  • 9Brown JM,Attardi LD.The role of apoptosis in cancer development and treatment response[J].Nat Rev Cancer,2005,5(3):231-234.
  • 10El-Bayoumy K,Sinha R.Mechanisms of mammary cancer chemoprevention by organoselenium compounds[J].Mutat Res,2004,551(1-2):181-197.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部